June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
D'Sa, S.

PF487 MAJOR RESPONSES IN MYD88 WILDTYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111)

Dimopoulos, M.; Opat, S.; Lee, H.-P.; More

HemaSphere. 3(S1):196, June 2019.

PF495 WHIMSICAL (WALDENSTRÖM'S MACROGLOBULINEMIA STUDY INVOLVING CART-WHEEL): A GLOBAL PATIENT-DERIVED DATA REGISTRY MAPPING TREATMENT AND QUALITY OF LIFE DATA

Tohidi-Esfahani, I.; Warden, A.; Malunis, E.; More

HemaSphere. 3(S1):200-201, June 2019.

PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3(S1):958, June 2019.

Author:
D‘Adda, M.
Author:
D’Adda, M.

S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3(S1):396-397, June 2019.

PS1190 R-INTERFERON TREATMENT BEFORE TKI START IMPROVES TREATMENT FREE REMISSION RATE (TFR) PARTICULARLY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH THE LESS FAVORABLE E13A2 BCR-ABL1 TRANSCRIPT TYPE

D’Adda, M.; Farina, M.; Passi, A.; More

HemaSphere. 3(S1):542, June 2019.

PS1462 SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY

Maffioli, M.; Giorgino, T.; Mora, B.; More

HemaSphere. 3(S1):673-674, June 2019.

S1646 THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY

Schieppati, F.; Russo, L.; Marchetti, M.; More

HemaSphere. 3(S1):761-762, June 2019.

Author:
D’Alò, F.
Author:
D’Amore, F.

S1599 RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY

Lugtenburg, P.; Brown, P.; van der Holt, B.; More

HemaSphere. 3(S1):736, June 2019.

Author:
D’Arco, A. M.
Author:
D’Arena, G.

PS1152 THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE

Innocenti, I.; Morelli, F.; Autore, F.; More

HemaSphere. 3(S1):522-523, June 2019.

Author:
D’Argenio, M.

PB2347 NIVOLUMAB AS A BRIDGE TO ALLOGENEIC TRASPLANTATION IN PATIENT WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE OF A SINGLE CENTER

Federico, V.; Matera, R.; Forese, P.; More

HemaSphere. 3(S1):1045, June 2019.

Author:
D’Ascola, D.
Author:
D’Auria, L.
Author:
D’Avola, A.
Author:
D’hont, I.

PF204 TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT

Depreter, B.; Weening, K.; Vandepoele, K.; More

HemaSphere. 3(S1):54, June 2019.

Author:
da Rosa, L.I.

PS1450 THE PHARMACOLOGICAL IGF1R-IRS1/2 INHIBITOR OSI-906 REDUCES ERYTHROID PROGENITORS AND INHIBITS STAT3 IN JAK2V617F KNOCKIN-MYELOPROLIFERATIVE NEOPLASM MICE

Fernandes, J.C.; Fenerich, B.A.; Coelho-Silva, J.L.; More

HemaSphere. 3(S1):667, June 2019.

PS1248 COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Ferrero, S.; Zaccaria, G.M.; Barbero, D.; More

HemaSphere. 3(S1):569-570, June 2019.

Author:
Da Viá, M.
Author:
Daar, S.
Author:
Daelemans, D.
Author:
Daffini, R.

PS1190 R-INTERFERON TREATMENT BEFORE TKI START IMPROVES TREATMENT FREE REMISSION RATE (TFR) PARTICULARLY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH THE LESS FAVORABLE E13A2 BCR-ABL1 TRANSCRIPT TYPE

D’Adda, M.; Farina, M.; Passi, A.; More

HemaSphere. 3(S1):542, June 2019.

Author:
Daga, S.
Author:
Dagdas, S.
Author:
Daguindau, N.

S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3(S1):3, June 2019.

Author:
Dahmash, F.

PS1052 AGE >70 YEARS, HIGH-RISK CYTOGENETICS, SORROR COMORBIDITY SCORE >1 AND BLAST COUNT>40% IN BM ARE RISK FACTORS FOR INDUCTION FAILURE OF STANDARD CHEMOTHERAPY WITH ANTHRACYCLINE AND CYTARABINE IN AML

Pannenbeckers, M.; Jehn, C.; Salwender, H.; More

HemaSphere. 3(S1):476, June 2019.

Author:
dahpy, M.
Author:
Dai, D.

PS1025 IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT NEWLY-DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

Roboz, G.J.; DiNardo, C.D.; Stein, E.M.; More

HemaSphere. 3(S1):461-462, June 2019.

PS1337 IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

Foran, J.M.; DiNardo, C.D.; Watts, J.M.; More

HemaSphere. 3(S1):610-611, June 2019.

Author:
Dai, S.

S107 FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Tedeschi, A.; Burger, J.; Barr, P.M.; More

HemaSphere. 3(S1):5-6, June 2019.

Author:
Dakhil, S.R. MD

S839 PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

Navada, S.C.; Garcia-Manero, G.; Atallah, E.; More

HemaSphere. 3(S1):373-374, June 2019.

Author:
Dakik, H.

PF200 CARBENOXOLONE REVERSES MICROENVIRONMENT-INDUCED CHEMORESISTANCE OF ACUTE MYELOID LEUKEMIA

Kouzi, F.; Zibara, K.; Picou, F.; More

HemaSphere. 3(S1):52-53, June 2019.

Author:
Dal, M. S.
Author:
Dal, M.S.
Author:
Dal Bello, R.

PF211 MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL

Dal Bello, R.; Adès, L.; Braun, T.; More

HemaSphere. 3(S1):57, June 2019.

Author:
Dal Lago, L.

PS1517 MILD COGNITIVE IMPAIRMENT, HYPOALBUMINEMIA, HIGH CRP AND GASTRO-INTESTINAL ULCER: 4 MARKERS OF FRAILTY WHICH IDENTIFY OLDER PATIENTS WITH MALIGNANT HEMOPATHIES WHO DON’T BENEFIT FROM CHEMOTHERAPY

Thibaud, V.; Deneve, L.; Dubruille, S.; More

HemaSphere. 3(S1):699, June 2019.

Author:
Dal Molin, A.
Author:
Dalal, M.

PS1256 CONTEMPORARY TREATMENT PATTERNS AND RESPONSE IN RELAPSE/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL) IN CLINICAL PRACTICE IN FRANCE, GERMANY ITALY, SPAIN AND THE UNITED KINGDOM

Illidge, T.; Bagot, M.; Waser, N.; More

HemaSphere. 3(S1):573-574, June 2019.

Author:
Dalby-Brown, W.

PF158 TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520

Marchesini, M.; Gherli, A.; Winter, A.-M. Lund; More

HemaSphere. 3(S1):31, June 2019.

Author:
Dale, D.C.
Author:
Daley, J.

PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE-CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

Prabhala, R.; Samur, M.; Talluri, S.; More

HemaSphere. 3(S1):246, June 2019.

Author:
Dalgaard, L.T.
Author:
Dalla Palma, B.

S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS

Gay, F.; Cerrato, C.; Rota Scalabrini, D.; More

HemaSphere. 3(S1):390-391, June 2019.

Author:
Dalla-Pozza, L.

PS938 INTENSIVE PAEDIATRIC THERAPY IS AS DELIVERABLE IN ADOLESCENTS AND YOUNG ADULTS AS CHILDREN WITH ALL - PRELIMINARY RESULTS OF THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP (ALLG) ALL06 STUDY

Greenwood, M.; Trahair, T.; Osborn, M.; More

HemaSphere. 3(S1):422, June 2019.

Author:
Dalle, J.-H.

PS943 SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE

Dourthe, M.E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3(S1):425, June 2019.

Author:
Dally, N.
Author:
Dam, M.J.

PS1438 DATA-DRIVEN ANALYSIS OF JAK2V617F KINETICS DURING INTERFERON-ALPHA2 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA AND RELATED NEOPLASMS

Skov, V.; Pedersen, R.K.; Andersen, M.; More

HemaSphere. 3(S1):663, June 2019.

Author:
Damaj, G.

S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3(S1):3, June 2019.

Author:
Damen, J.
Author:
Damianaki, A.

PB1881 EVALUATION OF THE QUANTITATIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATED HYPOGAMMAGLOBULINEMIA

Zavisanou, K.; Bizymi, N.; Ioneskou, K.; More

HemaSphere. 3(S1):857, June 2019.

Author:
Damiani, D.

PB1930 CORRELATION BETWEEN LEVELS OF EARLY MOLECULAR RESPONSE AND BCR-ABL TRANSCRIPT TYPE IN STABLE DMR ATTAINMENT IN CML PATIENTS TREATED WITH IMATINIB

Tiribelli, M.; Bonifacio, M.; Binotto, G.; More

HemaSphere. 3(S1):877-878, June 2019.

Author:
Damlaj, M.
Author:
Damm, F.

PS1003 HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA

Bullinger, L.; Valk, P.; Versluis, J.; More

HemaSphere. 3(S1):451, June 2019.

Author:
Dammag, E.
Author:
Damy, T.

PS1410 DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT

Gounot, R.; Lemonnier, F.; Dupuis, J.; More

HemaSphere. 3(S1):648, June 2019.

Author:
Dan, E.

S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3(S1):13-14, June 2019.

Author:
Danaee, A.
Author:
Danek, P.
Author:
Dang, D.
Author:
Dang, P.
Author:
Dang, R.

PF691 SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

Todd, S.; Infirri, S. Sardo; Miah, H.; More

HemaSphere. 3(S1):299-300, June 2019.

Author:
Dang Chi, V.L.

PF368 DYSREGULATION OF BACH2 AND FOXP1 GENES IN T AND B CELLS IS MORE PRONOUNCED IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGED-MATCHED HEALTHY DONORS WITH AN IMPACT ON SURVIVAL

De Silva, P.; Stamatopoulos, B.; Dang Chi, V.L.; More

HemaSphere. 3(S1):135-136, June 2019.

Author:
Danho, N.C.
Author:
Daniel, D.